Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

OBJECTIVES: Primary * Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with metastatic breast cancer. * Identify a tolerable, immunologically active dose level of this vaccine in these patients. Secondary * Evaluate the immune function in these patients before and after treatment with this vaccine. OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0. After completion of study treatment, patients are followed monthly for 9 months.